E-ISSN: 2405-819X
Intermittent intravenous administration of Iloprost in patients with idiopathic pulmonary arterial hypertension
PDF
Cite
Share
Request
Case Report
VOLUME: 2 ISSUE: 3
P: 114-118
September 2016

Intermittent intravenous administration of Iloprost in patients with idiopathic pulmonary arterial hypertension

IJCVA 2016;2(3):114-118
DOI: 10.1016/j.ijcac.2016.06.003
Majid Malekmohammad 1
Babak Sharif-Kashani 2
Fateme Monjazebi 3
Leila saliminejad 3
1. Tracheal Disease Research Center, NRITLD, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences,Tehran, Iran
2. Tobacco Prevention and Control Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran 1955841452, Iran
3. Chronic Respiratory Diseases Research Center, National Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
No information available.
No information available
Received Date: 12.05.2016
Accepted Date: 06.06.2016
PDF
Cite
Share
Request

ABSTRACT

Background and objectives: Because there is no cure for idiopathic pulmonary artery hypertension (IPAH), im- proving survival and stabilizing disease are key aims in any treatment strategy for patients with IPAH. Intrave- nous (IV) administration of prostacyclin positively affects the symptoms and hemodynamic of patients with IPAH. This study sought to assess the efficacy of cyclic Iloprost administration in Iranian patients with IPAH. Materials and methods: This longitudinal study was conducted on 20 patients with IPAH. Upon hospitalization, the patients received intermittent IV administration of Iloprost 6 hours a day for 5 days; this cycle was repeated every 6 weeks, total duration of treatment was 12 months. New York Heart Association/World Health Organization (NYHA/WHO) functional classification (FC), 6-minute walk test (6MWT), mean pulmonary arterial pressure (PAPm), right ventricular pressure (RVP), and serum level of N-terminal pro b-type natriuretic peptide (NT-proBNP) were assessed at baseline, during and after completion of treatment course. The data were analyzed using SPSS version 13. Results: The FC, PAPm, and RVP significantly decreased after the treatment (P b 0.001). No change occurred in the level of oxygen saturation during the 6MWT but the distance walked significantly increased after the interven- tion compared to baseline. Level of NT-proBNP significantly decreased in patients after treatment (P = 0.009). Conclusion: Intermittent IV administration of Iloprost decreases the FC, PAPm, RVP, and serum level of NT-proBNP and increases the distance walked in the 6MWT by patients.

Keywords: Iloprost Idiopathic pulmonary arterial hypertension Intermittent Intravenous

References

2024 ©️ Galenos Publishing House